Oragenics,
Inc. 4th Quarter
Update
Oragenics
is Scheduled to Sell Its Acclaimed Probiotic Oral Care Product
EvoraPlus™ Through Some Of The Country’s Biggest Mass Retailers
during 2010
Oragenics
Also Positions Company’s Probiotic Technology For Domestic And International
Licensing And Private Label Distribution Deals With Major Global Pharmaceutical
And Personal Care Companies
For Immediate
Release
Alachua, FL (Date) – Oragenics, Inc. (OTCBB: ORNI
www.oragenics.com) heads into the close
of 2009 with an extensive array of high-profile retail companies that are slated
to launch its core EvoraPlus™ and Teddy’s Pride™ brands in
2010. The fourth quarter has seen the mass retail launch of Oragenics’ flagship
EvoraPlus and Teddy’s Pride in A&P
Supermarkets and Pathmark, which together account for nearly 1,000 locations
across the country.
EvoraPlus
will make its debut in several major mass retailers through the second quarter
of 2010, leading off in early January with Hannaford Supermarkets’ pharmacies
covering Maine, Massachusetts, New Hampshire, New York and Vermont and Sweet Bay
Supermarkets covering Florida.
Following
the Hannaford and Sweetbay launches, EvoraPlus and Teddy’s Pride is
scheduled to be rolled-out by a number of top national retailers throughout the
first half of the year. As previously mentioned in its 10-Q filing for the third
quarter of 2009, the Company received written confirmation that EvoraPlus would be carried by
one of the country’s largest mass drug store chains. As a result, the Company
anticipates that this will place its EvoraPlus in over 7,000
locations nationwide. At present, this roll-out is scheduled for March 2010.
Oragenics has also received verbal confirmation that a second national drug
store chain has decided to include EvoraPlus in its upcoming
planagram, which should place Oragenics' products in several thousand additional
stores during the first half of the year.
Concurrently
with the retail distribution of its core product lines, Oragenics has started
negotiations with several leading domestic and international consumer products,
pharmaceutical and personal care manufacturers and distributors aimed at
licensing the Company’s patented probiotic technology ProBiora3™ for integration
into personal care and pet products, for the private labeling of Oragenics’
ProBiora3-based
products, and for establishing in-country distribution agreements on behalf of
EvoraPlus and Teddy’s Pride.
The media
has taken notice of Oragenics and its innovative probiotic oral care products.
The Company and its core products have been featured several times on FOX
television newscasts and the popular PBS series National Medical Report with Hugh
Downs. More than 800 newspapers have discussed EvoraPlus in their
editorial section and hundreds of health-oriented websites and grassroots
‘blogs’ have prominently featured both EvoraPlus and Teddy’s Pride with
unanimous positive reviews and ‘recommendations to purchase’. Oragenics and its
product line is scheduled to be featured on The Balancing Act, an
award-winning talk and
magazine show reaching
96 million homes that airs weekday mornings on Lifetime Channel during the
months of January and February.
Mr. David
Hirsch, President and CEO of Oragenics, Inc. has stated: “We are extremely
pleased with the progress we have made in executing our retail strategy through
the fourth quarter of 2009 and we continue to remain optimistic about our
prospects for 2010.”
Developed
by Dr. Jeffrey Hillman, D.M.D., Ph.D., and Chief Scientific Officer at
Oragenics, Inc., EvoraPlus
is the result of more than 25 years of research, which began at the
Harvard-affiliated Forsyth Institute in Boston and continued at Oragenics.
Through his research, Dr. Hillman found three strains of beneficial bacteria
that help maintain an optimal balance of beneficial bacteria in the mouth,
naming the patent-pending blend ProBiora3™, the active ingredient in EvoraPlus. 100% natural,
EvoraPlus is made in
the USA in an FDA registered and GMP certified facility ensuring both the
highest quality ingredients and complete integrity. For more information on
Oragenics and its products, please reference www.oragenics.com,
www.evoraplus.com, teddyspride.com and www.probiora3.com.
About
Oragenics, Inc.
Oragenics,
Inc. is a biopharmaceutical company engaged in developing unique proprietary
technologies, some of which are being commercialized and sold in the
over-the-counter consumer healthcare market. The company also has a number of
products in discovery, preclinical and clinical development, with a
concentration in the main therapeutic area of infectious diseases, diagnostics,
and oral health. The company is located in Progress Corporate Park at 13700
Progress Boulevard in Alachua, Florida, approximately 15 miles from the campus
of the University of Florida in Gainesville.
# #
#
CONTACT:
SSA Public Relations
(818)
907-5929
Steve
Syatt
ssyatt@ssapr.com
Cara
Downs
cdowns@ssapr.com
Oragenics,
Inc.
(386)
418-4018
David
Hirsch, President and CEO
dhirsch@oragenics.com
Safe Harbor Statement: Under
the Private Securities Litigation Reform Act of 1995: This release includes
forward-looking statements that reflect the Company’s current views with respect
to future events and financial performance. These forward-looking statements are
based on management’s beliefs and assumptions and information currently
available. The words “believe,” "should," “expect,” “anticipate,” “intend,”
“estimate,” “project” and similar expressions that do not relate solely to
historical matters identify forward-looking statements. Investors should be
cautious in relying on forward-looking statements because they are subject to a
variety of risks, uncertainties, and other factors that could cause actual
results to differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to (i)
cancellation by retailers of existing orders, pending orders or plans
of future orders or changes to existing orders, (ii) the inability of the
Company to receive an initial order following inclusion by a retailer of
the Company's product in a planagram or any subsequent orders, (iii)
changes in a retailers planagram, (iv) changes in estimated times for
rollout of the Company's products or in the number of estimated locations
in which the product will be available, (v) changes in the timing of the
featuring of the Company's products in media outlets or cancellation of such
pending features, and (vi) those factors set forth in our most
recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and
other factors detailed from time to time in filings with the Securities and
Exchange Commission. We expressly disclaim any responsibility to update
forward-looking statements.